[soccertese]

The governing board of California Institute for Regenerative Medicine (Palo Alto, CA), the state stem-cell agency, approved the concept for up to $243 million round of funding to move stem cell-based therapies to clinical trial. The funding will support multidisciplinary teams of researchers working toward filing a request with the US Food and Drug Administration to begin clinical trials, or completing an early stage trial, within four years.